Effect and safety comparison of anticoagulant therapy of different doses of Rivaroxaban and Warfarin in elderly patients with non-valvular atrial fibrillation
WU Xuan1 XU Xue-qing2 WANG Jia-shu3 WANG Kun1
1. Department of Emergency, Wuhan No.7 Hospital
2. ICU, Wuhan No.7 Hospital
3. Department of Cardiology, Wuhan No.7 Hospital
Abstract：Objective To explore the effect and safety of anticoagulant therapy of different doses of Rivaroxaban and Warfarin in the treatment of elderly patients with non-valvular atrial fibrillation. Methods A total of 120 elderly patients with non-valvular atrial fibrillation treated in Wuhan No.7 Hospital from April 2015 to April 2019 were selected as the research objects. They were divided into the low-dose Rivaroxaban group (30 cases), the regular-dose Rivaroxaban group (30 cases), the high-dose Rivaroxaban group (30 cases), and the Warfarin group (30 cases) by random number table method. Patients in the low-dose Rivaroxaban group were treated with 5 mg Rivaroxaban, those in the regulardose Rivaroxaban group were treated with 10 mg Rivaroxaban, those in the high-dose Rivaroxaban group were treated with 20 mg Rivaroxaban, and those in the Warfarin group were treated with Warfarin. The coagulation function, thromboembolic events, bleeding events and adverse reactions of the four groups were compared. Results Comparison of coagulation function indexes before treatment among the four groups showed no statistically significant differences (P>0.05). Comparison of coagulation function indexes after treatment among the four groups showed no statistically significant differences (P>0.05). The prothrombin time (PT) of the four groups after treatment was longer than that before treatment, and the antithrombin Ⅲwas higher than that before treatment, with statistically significant differences (P<0.05). D-dimer levels after treatment in the four groups were lower than those before treatment, and the differences were statistically significant (P<0.05). Comparison of the total incidence of thromboembolic events among the four groups showed no statistically significant differences (P>0.05). Comparison of the total incidence of bleeding events among the four groups showed no statistically significant differences (P>0.05). The total incidence rates of adverse reactions in the four groups were compared, and the differences were not statistically significant (P>0.05). Conclusion Rivaroxaban at different doses and Warfarin are equally effective and safe in anticoagulation therapy for elderly patients with non-valvular atrial fibrillation. In view of the limitations of Warfarin therapy, low-dose Rivaroxaban should be the first choice for anticoagulation therapy in elderly patients with non-valvular atrial fibrillation.
吴宣；许雪清；汪家淑；王昆. 不同剂量利伐沙班与华法林对高龄非瓣膜性心房颤动患者的抗凝治疗效果及安全性比较[J]. 中国当代医药, 2021, 28(3): 90-94.
WU Xuan； XU Xue-qing； WANG Jia-shu； WANG Kun. Effect and safety comparison of anticoagulant therapy of different doses of Rivaroxaban and Warfarin in elderly patients with non-valvular atrial fibrillation. 中国当代医药, 2021, 28(3): 90-94.
京公网安备 11010502046607号